Skip to main content
. Author manuscript; available in PMC: 2021 Jun 26.
Published in final edited form as: Vaccine. 2020 May 29;38(31):4869–4876. doi: 10.1016/j.vaccine.2020.05.036

Figure 3. Higher frequency of detectable IgG1 and IgG4 Tdap-specific antibodies in mother-infant pairs that received Tdap during pregnancy.

Figure 3.

Frequency of vaccine-elicited IgG1 (A), IgG2 (B), IgG3 (C), and IgG4 (D) was determined in both maternal and cord blood plasma. The majority of mothers and infants had detectable levels of IgG1 against the vaccines tested. A high proportion of mothers and infants also had vaccine-specific IgG4 antibodies whereas the frequency of vaccine-elicited IgG2 and IgG3 responses was generally lower. * P < 0.05, ** P < 0.01, *** P < 0.001, Chi-Square Test of Independence.